CD19 and acute lymphoblastic leukemia: Against the backdrop of reports from two recent clinical trials about B-ALL cells undergoing a switch from the lymphoid lineage towards a myeloid phenotype to abrogate CD19 expression and evade destruction by CD19-CAR-T cells, the quest for non-lineage-restricted backup antigens has gained attraction [89].